Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

70 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Real World Efficacy and Safety of Sofosbuvir + Velpatasvir + Voxilaprevir in Romanian Patients with Genotype 1b HCV Infection Non-reponders to DAAs Therapy.
Gheorghe L, Preda C, Trifan A, Manuc M, Stanciu C, Istratescu D, Popescu CP, Diculescu MM, Tieranu CG, Manuc T, Stroie TG, Iacob SM, Iliescu L. Gheorghe L, et al. Among authors: iliescu l. J Gastrointestin Liver Dis. 2022 Dec 17;31(4):437-443. doi: 10.15403/jgld-4472. J Gastrointestin Liver Dis. 2022. PMID: 36535062 Free article.
Efficacy and Safety of Ledispavir/Sofosbuvir with or without Ribavirin in patients with Decompensated Liver Cirrhosis and Hepatitis C Infection: a Cohort Study.
Gheorghe LS, Preda C, Iliescu L, Istratescu D, Chifulescu AE, Pop CS, Trifan A, Stanciu C, Diculescu M, Voiosu T, Baicus C, Tugui L, Iacob S, Tieranu C, Meianu C, Manuc M. Gheorghe LS, et al. Among authors: iliescu l. J Gastrointestin Liver Dis. 2020 Sep 9;29(3):385-390. doi: 10.15403/jgld-2448. J Gastrointestin Liver Dis. 2020. PMID: 32919421 Free article.
Occurrence and recurrence of hepatocellular carcinoma in patients with HCV genotype 1b related cirrhosis treated with Ledipasvir + Sofosbuvir ± Ribavirin.
Pop CS, Preda CM, Manuc M, Gheorghe LS, Istratescu D, Chifulescu AE, Voiosu T, Diculescu M, Tieranu C, Iliescu L. Pop CS, et al. Among authors: iliescu l. J Gastrointestin Liver Dis. 2020 Dec 13;29(4):690-691. doi: 10.15403/jgld-3148. J Gastrointestin Liver Dis. 2020. PMID: 33331348 Free article. No abstract available.
Effectiveness of 8- and 12-Week Treatment with Ombitasvir/ Paritaprevir/Ritonavir and Dasabuvir in Treatment-Naïve HCV Patients in a Real-Life Setting in Romania: the AMETHYST Study.
Trifan A, Stanciu C, Iliescu L, Sporea I, Baroiu L, Diculescu M, Luca MC, Miftode E, Cijevschi C, Mihai C, Sparchez ZA, Pojoga C, Streinu-Cercel A, Gheorghe L. Trifan A, et al. Among authors: iliescu l. J Gastrointestin Liver Dis. 2021 Mar 13;30(1):88-93. doi: 10.15403/jgld-3373. J Gastrointestin Liver Dis. 2021. PMID: 33723561 Free article.
A Real-World Study to Compare the Safety and Efficacy of Paritaprevir/Ombitasvir/Ritonavir and Dasabuvir, with or without Ribavirin, in 587 Patients with Chronic Hepatitis C at the Fundeni Clinical Institute, Bucharest, Romania.
Bacinschi X, Popescu GC, Zgura A, Gales L, Rodica A, Mercan A, Serban D, Haineala B, Toma L, Iliescu L. Bacinschi X, et al. Among authors: iliescu l. Med Sci Monit. 2022 Jul 5;28:e936706. doi: 10.12659/MSM.936706. Med Sci Monit. 2022. PMID: 35787600 Free PMC article.
70 results